Cite
HARVARD Citation
Fischer, H. et al. (2020). Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. Neuro-oncology. 22 (6), pp. 819-829. [Online].